$NTRA

Sheena Jonathan sold $330K of NTRA (indirect holdings)

Sheena Jonathan sold 1,500 indirectly-held shares of Natera, Inc. (NTRA) at an average of $219.87 ($218.14–$222.14, $0.33M total) across 9 trades on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Jun 23, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount ($329,809.76) and that it was executed under a pre-arranged Rule 10b5-1 plan; no other company-specific developments are provided.

02

Market read

Primarily a sentiment/positioning datapoint for NTRA; not a fundamental catalyst by itself.

03

What to watch

The filing is indirect holdings and multi-trade execution; without context on total insider activity or remaining plan size, directional inference is limited.

Relevance 3/10Novelty 3/10Timing: after-hours/filing update (Form 4 filed 2026-06-22 for trades dated 2026-06-17)

Background

The article is a SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold about $329.8K of NTRA shares via an open-market sale under a 10b5-1 plan on 2026-06-17.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless paired with other new fundamentals.

Evidence & confidence

This is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and no accompanying company-specific news (earnings, guidance, deal, or regulatory action).

Market effects

Minimal; single-company insider sale without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may not reflect bearish expectations; traders may discount it entirely.

Key entities

  • Natera, Inc.

    Issuer of the Form 4 insider transaction; director Sheena Jonathan sold shares under a 10b5-1 plan.

  • Sheena Jonathan

    Director reporting an indirect open-market sale of 1,500 shares across nine trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.